Massachusetts Financial Services
ABCL icon

Massachusetts Financial Services’s AbCellera Biologics ABCL Stock Holding History

Massachusetts Financial Services’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-46,016
Closed -$466K – 840
2022
Q4 		$466K Sell
46,016
-35,140
-43% -$406K ﹤0.01% 819
2022
Q3 		$803K Buy
+81,156
New +$890K ﹤0.01% 792

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services's ABCL Position: Q1 2023 in Review

Massachusetts Financial Services sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 46,016 shares — an estimated $466K sold.

Massachusetts Financial Services first reported a position in ABCL in Q3 2022 and held it in 2 quarters. The position peaked at $803K in Q3 2022. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

  • Massachusetts Financial Services reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
  • Massachusetts Financial Services sold 46,016 AbCellera Biologics shares in Q1 2023, an estimated $466K.
  • Massachusetts Financial Services first reported a position in AbCellera Biologics in Q3 2022 and held it in 2 quarters.
  • Massachusetts Financial Services's AbCellera Biologics position peaked at $803K in Q3 2022.
  • 183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on Massachusetts Financial Services's 13F filing for Q1 2023, filed 10 May 2023.